Good results were reported by the company in 2009, from a North American Phase III clinical trial comparing it with oral vancomycin for the treatment of Clostridioides difficile infection. The study met its primary endpoint of clinical cure, showing that<unk>  was non-inferior to oral vancomycin (92.1% vs. 89.8%). In addition, the study met its secondary endpoint of recurrence: 13.3% of the subjects had a recurrence with<unk>  vs. 24.0% with oral vancomycin. The study also met its exploratory endpoint of global cure (77.7% for<unk>  vs. 67.1% for vancomycin). Clinical cure was defined as patients requiring no further therapy for the treatment of 'Clostridioides difficile infection two days after completion of study medication. Global cure was defined as patients who were cured at the end of therapy and did not have a recurrence in the next four weeks.<unk>  was shown to be as good as the standard-of-care, vancomycin, for treating Clostridioides difficile infection in a Phase III clinical trial published in February 2011. The authors also reported significantly fewer recurrences of infection, a frequent problem with C. difficile, and similar drug side effects. Based on a multicenter clinical trial,<unk>  was reported well tolerated in children with Clostridioides difficile–associated diarrhea and has a pharmacokinetic profile in children similar to that in adults. Regarding the high budget to spend for<unk> , a systematic literature review published in 2017, showed that<unk>  was demonstrated to be cost-effective versus metronidazole and vancomycin in patients with Clostridioides difficile infection.
Fidaxomicin
Milbemycin oxime
Plazomicin
Rifabutin
Miproxifene phosphate
Milbemycin
Amifampridine
Anthracimycin